GlaxoSmithKline (GSK) is setting up a state-of-the-art vaccines manufacturing
facility at Nasik in India. This will be GSK's first manufacturing site to
co-house a pharmaceutical and vaccine manufacturing. The facility is expected to
commence operations by early 2006. Its vaccines are currently developed,
produced, filled and packaged at its vaccines headquarters and manufacturing
facility at Rixensart, Belgium.
The new GSK vaccine facility in Nashik will be under the close supervision of
GSK Biologicals, Belgium. Patrick Florent, vice president, global industrial
operations, GSK Biologicals, laid the foundation stone of the facility. S
Kalyanasundaram, managing director, GSK India and vice president, South Asia,
GSK International, said, “This new vaccine facility reflects the company's
commitment to India and recognizes the high quality skills and science base in
India.�
